56 related articles for article (PubMed ID: 35942238)
1. A commentary on "PI3K-α/mTOR/BRD4 inhibitor alone or in combination with other anti-virals blocks replication of SARS-CoV-2 and its variants of concern including Delta and Omicron".
Muthu S; Venkatesh S
Clin Transl Discov; 2022 Jun; 2(2):e87. PubMed ID: 35942238
[No Abstract] [Full Text] [Related]
2. PI3K-α/mTOR/BRD4 inhibitor alone or in combination with other anti-virals blocks replication of SARS-CoV-2 and its variants of concern including Delta and Omicron.
Acharya A; Pathania AS; Pandey K; Thurman M; Vann KR; Kutateladze TG; Challagundala KB; Durden DL; Byrareddy SN
Clin Transl Med; 2022 Apr; 12(4):e806. PubMed ID: 35390226
[No Abstract] [Full Text] [Related]
3. Blockade of SARS-CoV-2 infection in vitro by highly potent PI3K-α/mTOR/BRD4 inhibitor.
Acharya A; Pandey K; Thurman M; Challagundala KB; Vann KR; Kutateladze TG; Morales GA; Durden DL; Byrareddy SN
bioRxiv; 2021 Mar; ():. PubMed ID: 33688653
[TBL] [Abstract][Full Text] [Related]
4. Correlation Analysis of Anti-SARS-CoV-2 RBD IgG and Neutralizing Antibody against SARS-CoV-2 Omicron Variants after Vaccination.
Takheaw N; Liwsrisakun C; Chaiwong W; Laopajon W; Pata S; Inchai J; Duangjit P; Pothirat C; Bumroongkit C; Deesomchok A; Theerakittikul T; Limsukon A; Tajarernmuang P; Niyatiwatchanchai N; Trongtrakul K; Kasinrerk W
Diagnostics (Basel); 2022 May; 12(6):. PubMed ID: 35741126
[TBL] [Abstract][Full Text] [Related]
5. Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern.
Mohandas S; Yadav PD; Sapkal G; Shete AM; Deshpande G; Nyayanit DA; Patil D; Kadam M; Kumar A; Mote C; Jain R
EBioMedicine; 2022 May; 79():103997. PubMed ID: 35405385
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 Omicron Induces Enhanced Mucosal Interferon Response Compared to other Variants of Concern, Associated with Restricted Replication in Human Lung Tissues.
Alfi O; Hamdan M; Wald O; Yakirevitch A; Wandel O; Oiknine-Djian E; Gvili B; Knoller H; Rozendorn N; Golan Berman H; Adar S; Vorontsov O; Mandelboim M; Zakay-Rones Z; Oberbaum M; Panet A; Wolf DG
Viruses; 2022 Jul; 14(7):. PubMed ID: 35891570
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo.
Hui KPY; Ho JCW; Cheung MC; Ng KC; Ching RHH; Lai KL; Kam TT; Gu H; Sit KY; Hsin MKY; Au TWK; Poon LLM; Peiris M; Nicholls JM; Chan MCW
Nature; 2022 Mar; 603(7902):715-720. PubMed ID: 35104836
[TBL] [Abstract][Full Text] [Related]
8. Cysteamine exerts in vitro antiviral activity against the SARS-CoV-2 Delta and Omicron variants.
Alonzi T; Aiello A; Repele F; Falasca L; Francalancia M; Garbuglia AR; Delogu G; Nicastri E; Piacentini M; Goletti D
Cell Death Discov; 2022 Jun; 8(1):288. PubMed ID: 35705564
[TBL] [Abstract][Full Text] [Related]
9. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
[TBL] [Abstract][Full Text] [Related]
10. OraSure InteliSwab
Weishampel ZA; Young J; Fischl M; Fischer RJ; Donkor IO; Riopelle JC; Schulz JE; Port JR; Saturday TA; van Doremalen N; Berry JD; Munster VJ; Yinda CK
Viruses; 2022 Mar; 14(3):. PubMed ID: 35336950
[TBL] [Abstract][Full Text] [Related]
11. Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants.
Lu J; Yin Q; Pei R; Zhang Q; Qu Y; Pan Y; Sun L; Gao D; Liang C; Yang J; Wu W; Li J; Cui Z; Wang Z; Li X; Li D; Wang S; Duan K; Guan W; Liang M; Yang X
Virol Sin; 2022 Apr; 37(2):238-247. PubMed ID: 35527227
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern.
Odak I; Schultze-Florey CR; Hammerschmidt SI; Ritter C; Willenzon S; Friedrichsen M; Ravens I; Sikora R; Bayir LM; Gutierrez Jauregui R; Bernhardt G; Stankov MV; Cossmann A; Hansen G; Krey T; Cornberg M; Koenecke C; Behrens GMN; Bošnjak B; Förster R
Front Immunol; 2022; 13():863039. PubMed ID: 35359969
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron.
Zhu Y; Dong X; Liu N; Wu T; Chong H; Lei X; Ren L; Wang J; He Y
Emerg Microbes Infect; 2022 Dec; 11(1):1819-1827. PubMed ID: 35786417
[TBL] [Abstract][Full Text] [Related]
14. Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein.
Kumar S; Thambiraja TS; Karuppanan K; Subramaniam G
J Med Virol; 2022 Apr; 94(4):1641-1649. PubMed ID: 34914115
[TBL] [Abstract][Full Text] [Related]
15. Has Omicron Changed the Evolution of the Pandemic?
Lundberg AL; Lorenzo-Redondo R; Ozer EA; Hawkins CA; Hultquist JF; Welch SB; Prasad PVV; Oehmke JF; Achenbach CJ; Murphy RL; White JI; Havey RJ; Post LA
JMIR Public Health Surveill; 2022 Jan; 8(1):e35763. PubMed ID: 35072638
[TBL] [Abstract][Full Text] [Related]
16. Is the SARS CoV-2 Omicron Variant Deadlier and More Transmissible Than Delta Variant?
Duong BV; Larpruenrudee P; Fang T; Hossain SI; Saha SC; Gu Y; Islam MS
Int J Environ Res Public Health; 2022 Apr; 19(8):. PubMed ID: 35457468
[TBL] [Abstract][Full Text] [Related]
17. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
[TBL] [Abstract][Full Text] [Related]
18. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
[TBL] [Abstract][Full Text] [Related]
19. Characteristic analysis of Omicron-included SARS-CoV-2 variants of concern.
Yang H; Liu P; Zhang Y; Du T; Zhou Y; Lu S; Peng X
MedComm (2020); 2022 Jun; 3(2):e129. PubMed ID: 35434714
[TBL] [Abstract][Full Text] [Related]
20. Overlapping Delta and Omicron Outbreaks During the COVID-19 Pandemic: Dynamic Panel Data Estimates.
Lundberg AL; Lorenzo-Redondo R; Hultquist JF; Hawkins CA; Ozer EA; Welch SB; Prasad PVV; Achenbach CJ; White JI; Oehmke JF; Murphy RL; Havey RJ; Post LA
JMIR Public Health Surveill; 2022 Jun; 8(6):e37377. PubMed ID: 35500140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
